Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in montevideo, Uruguay

Pediatric Infectious Disease Journal

Volumn 30, Issue 8, 2011, Pages 669-674

  Pírez, María Catalina ^a   Algorta, Gabriela ^a   Cedrés, Alejandra ^b   Sobrero, Helena ^b   Varela, Adriana ^b   Giachetto, Gustavo ^a   Montano, Alicia ^a  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b Centro Hospitalario Pereira Rossell   (Uruguay)

Author keywords

meningitis; pneumonia; Streptococcus pneumoniae; Uruguay; vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ARTICLE; CHILD; COMMUNITY ACQUIRED PNEUMONIA; GROUPS BY AGE; HEALTH PROGRAM; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; PNEUMOCOCCAL MENINGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEROTYPE; STREPTOCOCCUS PNEUMONIA; URUGUAY; VACCINATION; VACCINE FAILURE;

EID: 79960622105     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182152bf1     Document Type: Article

References (35)

1. Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2:25-32. (Pubitemid 36109303)
2. Mulholland K. Magnitude of the problem of childhood pneumonia. Lancet. 1999;354:590-592. (Pubitemid 29381385)
3. Ferrari AM, Pírez MC, Rubio I, et al. Estrategia de atención de niños hospitalizados por infecciones respiratorias agudas bajas. Rev Saude Publica. 2002;36:291-300.
4. Epidemiología. Notificación Obligatoria de Enfermedades. Available at: www.msp.gub.uy. Accessed February 3, 2011.
5. Hortal M, Estevan M, Iraola I, et al. Determinación con base poblacional de la carga de enfermedad de la neumonía consolidante en niños menores de 5 años de edad (Uruguay, Junio 2001/Mayo 2004). Arch Pediatr Uruguay. 2005;76:326-327.
6. Pírez MC, Martínez O, Ferrari AM, et al. Standard case management of pneumonia in hospitalized children in Uruguay, 1997-1998. Pediatr Infect Dis J. 2001;20:283-289. (Pubitemid 32240268)
7. Giachetto G, Telechea H, Speranza N, et al. Costo-efectividad de la vacunación universal antineumocócica en Uruguay. Rev Panam Salud Pública. 2010;8:92-99.
8. Pírez MC, Berrondo C, Giacometti M, et al. Neumonía bacteriana adquirida en la comunidad en niños hospitalizados. Arch Pediatr Uruguay. 2003;74: 6-14.
9. Ferrari AM, Pírez MC, Martínez A, et al. Cambios en la etiología de la neumonía bacteriana adquirida en la comunidad. Uruguay 1998-2004. Rev Chilena Infectol. 2007;24:45-52.
10. Hortal M, Sehabiague G, Camou T, et al. Pneumococcal pneumonia in hospitalized children and potential prevention with different vaccine formulations. J Pediatr. 2008;151:850-853.
11. Di Fabio JL, Castañeda E, Agudelo CI, et al. Evolution of Streptococcus pneumoniae serotypes and penicillin susceptibility in Latin American, SIREVA-Vigía group. 1993-1999. Pediatric Infect Dis J. 2001;344:403-409.
12. Hortal M, Lovgren M, Di Fabio JL, et al. Antibiotic resistance in Streptococcus pneumoniae in six Latin American countries 1993-1999 surveillance. Microb Drug Resist. 2001;7:91-401.
13. Hortal M, Camou T, Palacio R, et al. y el grupo OPS/SIREVA-Uruguay. Vigilancia de las neumococcias del niño hospitalizado: su prevención específica (1994-2000). Rev Med Uruguay. 2002;18:6-75.
14. Epidemiologia. Certificado esquema de vacunación año 2008. April 26, 2008. Available at: www.msp.gub.uy. Accessed February 3, 2011.
15. Pírez MC, Montano A, Rubio I, et al. Neumonía. Meningoencefalitis aguda supurada. Atención Pediátrica. Atención Pediátrica. Pautas de diagnóstico, tratamiento y prevención. 6.a ed. Montevideo, Oficina del Libro FEFMUR; 2007.
16. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 20th Informational supplement M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
17. Estimating vaccine-preventable child mortality in the Americas. Panamerican Health Organization Immunization Newsletter. 2006;28:5-6.
18. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Weekly Epidemiol Rev. 2007;82:93-104.
19. Centers for Disease Control and Prevention. Progress in Introduction of Pneumococcal Conjugate Vaccine-Worldwide, 2000-2008. Morb Mortal Wkly Rep. 2008;57:1148-1151.
20. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:2-41.
21. Deceuninck G, De Wals, P, Boulianne N, et al. Effectiveness of pneumococcal conjugate vaccine using a 2-1 infant schedule in Quebec, Canada. Pediatr Infect Dis J. 2010;29:1-4.
22. Vestrheim DF, Lovoll O, Aaberge IS, et al. Effectiveness of a 2-1 dose schedule pneumococcal conjugate vaccination programme on invasive PD among children in Norway. Vaccine. 2008;26:3277-3281.
23. Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010;16:816-823.
24. Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine-United States, 1997-2006. Morb Mortal Wkly Rep. 2009;58:1-4.
25. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186. (Pubitemid 46527876)
26. Koshy E, Murray J, Bottle A, et al. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax. 2010;65:770-774.
27. Patrzałek M, Albrecht P, Sobczynski M. Significant decline in pneumonia admission rate after the introduction of routine 2-1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7)in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis. 2010;29: 787-792.
28. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics. 2007;119:707-715. (Pubitemid 46556669)
29. Wals PD, Carbon M, Sévin E, et al. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J. 2009;28:e271-e275.
30. Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2: e00309-e00310.
31. Hsu He, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244-256.
32. Tsai Ch J, Griffin MR, Nuorti JP, et al. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United Satates. Clin Infect Dis. 2008;46:1664-1672. (Pubitemid 351706762)
33. Hausdorff WP. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine. 2007;25:2406-2412. (Pubitemid 46366120)
34. Rommery MG, Hull MW, Gustafson R, et al. Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished urban population. Clin Infect Dis. 2008;47:768-774.
35. Dagan R, Grdstein S, Belmaker I, et al. An outbreak of Streptococcus pneumoniae serotype 1 in a closed community in Southern Israel. Clin Infect Dis. 2000;30:319-321. (Pubitemid 30131540)